Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Gains from Sales and Divestitures (2017 - 2025)

Historic Gains from Sales and Divestitures for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Puma Biotechnology's Gains from Sales and Divestitures fell 987.03% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 987.03%. This contributed to the annual value of $1.4 million for FY2024, which is 720.93% up from last year.
  • Per Puma Biotechnology's latest filing, its Gains from Sales and Divestitures stood at $1.2 million for Q3 2025, which was down 987.03% from $731009.0 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Gains from Sales and Divestitures ranged from a high of $1.4 million in Q4 2024 and a low of $189625.0 during Q1 2022
  • For the 5-year period, Puma Biotechnology's Gains from Sales and Divestitures averaged around $807027.2, with its median value being $774455.0 (2021).
  • Per our database at Business Quant, Puma Biotechnology's Gains from Sales and Divestitures soared by 10973.58% in 2021 and then plummeted by 2048.38% in 2022.
  • Quarter analysis of 5 years shows Puma Biotechnology's Gains from Sales and Divestitures stood at $1.1 million in 2021, then fell by 6.55% to $1.0 million in 2022, then increased by 27.84% to $1.3 million in 2023, then grew by 7.21% to $1.4 million in 2024, then dropped by 12.36% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $731009.0 for Q2 2025, and $509340.0 during Q1 2025.